Frank X Leonard sold $528k of NVCR
EVP, Pres., Novocure Oncology at NovoCure Ltd. 30,196 shares at an average of $17.50, traded Jun 2, 2025, filed Jun 4, 2025.
Score components
- +15RoleOfficer
- +18Trade size$528k at market
- +5Share of holdings soldSold 15% of holdings
- +15Cluster9 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-004426, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 2, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -21,717 | $17.22 | $374k | 176,931 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -6,600 | $17.99 | $119k | 170,331 | Jun 4, 2025 |
| Jun 2, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -1,879 | $19.01 | $36k | 168,452 | Jun 4, 2025 |
Related signals
Other insiders at NovoCure Ltd and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $85k 6,412 shares | -3% | |
| 57Moderate | NovoCure Ltd | William F Doyle Executive Chairman | $933k 71,887 shares | -18% | |
| 64Notable | NVCRbuy NovoCure Ltd | Ashley Cordova Chief Executive Officer | $997k 81,550 shares | +23% | |
| 56Moderate | NVCRbuy NovoCure Ltd | Christoph Brackmann Chief Financial Officer | $232k 20,000 shares | +17% | |
| 35Weak | NovoCure Ltd | Jeryl L Hilleman director | $17k 999 shares | -15% | |
| 30Weak | NovoCure Ltd | David Hung director | $17k 999 shares | -8% | |
| 30Weak | NovoCure Ltd | Gabriel Leung director | $17k 999 shares | -1% | |
| 30Weak | NovoCure Ltd | Martin J. Madden director | $17k 999 shares | -5% | |
| 30Weak | NovoCure Ltd | W Anthony Vernon director | $17k 999 shares | -1% | |
| 35Weak | NovoCure Ltd | Allyson J Ocean director | $17k 999 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.